Cross-sectional study of the distribution of cardiovascular diseases and risk factors in patients with prostate cancer with potential indications for endocrine therapy

Objective: this study aims to evaluate the prevalence of cardiovascular diseases (CVD) and associated risk factors in patients with prostate cancer (PCa) prior to initiation of endocrine therapy (ET), as a basis for reducing treatment-related complications and improving patient outcomes.
Materials and Methods. A total of 59 newly diagnosed, treatment-naïve PCa patients with potential indications for ET were enrolled at Sechenov University Clinical Hospital No. 1 between May 2018 and July 2022. Clinical and laboratory data were collected, and cardiovascular risk was assessed using ASCVD stratification.
Results. 83% of patients had at least one CVD; hypertension (79%) was the most prevalent condition. Blood pressure control was insufficient among patients at high cardiovascular risk. Dyslipidemia was present in 61%, mainly characterized by low HDL-C and elevated triglycerides. Only 19% of patients were on lipid-lowering therapy, and LDL-C target attainment was especially poor among high-risk patients.
Conclusion. The high prevalence of CVD and poor control of modifiable risk factors prior to ET initiation emphasize the need for early cardiovascular risk assessment and management. A multidisciplinary care model is essential to optimize treatment outcomes in PCa patients.

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.

2. Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38-52.

3. Leong DP, Fradet V, Shayegan B, et al. Cardiovascular risk in men with prostate cancer: Insights from the RADICAL PC study. J Urol. 2020;203(6):1109-1116.

4. Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889-3897.

5. Ng HS, Koczwara B, Roder D, et al. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis. 2018;21(3):403-410.

6. Veccia A, Maines F, Kinspergher S, et al. Cardiovascular toxicities of systemic treatments of prostate cancer. Nat Rev Urol. 2017;14(4):230-243.

7. Gandaglia G, Sun M, Popa I, et al. Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourin Cancer. 2015;13(3):e123-e130.

8. Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39-46.

9. Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386-396.

10. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448-3456.

11. Kunath F, Jensen K, Pinart M, et al. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2019;6(6):CD003506.

12. Diaconu R, Donoiu I, Mirea O, Bălşeanu TA. Testosterone, cardiomyopathies, and heart failure: a narrative review. Asian J Androl. 2021;23(4):348-356.

13. Kelly WK, Gomella LG. Androgen deprivation therapy and competing risks. JAMA. 2011;306(21):2382-2383.

14. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3):194-201.

15. Kolinsky M, de Bono JS. The ongoing challenges of targeting the androgen receptor. Eur Urol. 2016;69(5):841-843.

16. Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65(4):704-709.

17. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006;175(1):27-34.

18. Hedlund PO, Johansson R, Damber JE, et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol. 2011;45(5):346-353.

19. Smith MR, Saad F, Egerdie B, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271-3276.

20. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456.

21. Rezaei MM, Rezaei MM, Ghoreifi A, et al. Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Can Urol Assoc J. 2016;10(9-10):E300-E305.

22. Gupta D, Lee Chuy K, Yang JC, et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract. 2018;14(10):580-587.

23. Gagliano-Jucá T, Travison TG, Kantoff PW, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer. J Endocr Soc. 2018;2(5):485-496.

24. Smith MR, Klotz L, Persson BE, Olesen TK, et al. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, openlabel, parallel-group phase III trial in patients with prostate cancer. J Urol. 2010;184(6):2313-2319.